Conference Information

Welcome message

Pulsus Group cordially invites you to its new event, the International Conference on Biomarkers, which will be held in Paris, France, on October 12-14, 2023. It includes a keynote address, innovators and professors from various cancer treatment facilities, and a panel discussion.

The Biomarkers 2023 Platform brings together well-known figures and specialists from pharmacy, medicine, and research who share similar ideologies and interests in common ailments, particularly those found in oncology.

Biomarkers 2023 brings together exceptional and international experts, scientists, and decision-makers from academia and industry to discuss and learn about advances in biomarker research on access while exchanging knowledge, innovations, and research as well as expertise in the field of cancer treatments.

Biomarkers 2023 will feature a two-day scientific conference, business meeting, trade show, and fair with the theme "Biomarkers Current Perspective and Future Prospects"

Biomarkers 2023 will provide a unique and international forum for specialists, scientists, and decision-makers from academia and industry from all over the world to share knowledge, innovations, research, and expertise in the field of cancer treatments.

Biomarkers 2023 brings together professionals from various fields to satisfy and discuss the longer term of clinical research and, as a result, the necessity of biomarkers in today's world to survive with better health. This meeting will cover technological advancements, new scientific discoveries, and current biomarker trends. There will be discussions, keynote addresses, poster presentations, and other activities. You will be able to learn more about biomarkers at this meeting.

Benefits of attending:

Hear from and meet top academic and corporate innovators in diagnostics, clinical development, translational medicine, and Biomarkers.

Learn about the most recent Biomarkers integration in drug development by reviewing case studies from renowned pharmaceutical companies in a variety of therapeutic areas, including immunology, neurology, NASH, and oncology.

Discover cutting-edge digital marker applications and critical Biomarkers for detection, monitoring, and diagnosis. The current discussions are focused on early cancer detection.

Discuss the use of Biomarkers in preclinical and clinical research, including trial planning, data analysis, assay development, patient classification, and the significance of safety and efficacy markers.

Take advantage of a highly engaging event schedule that includes a variety of panels, workshops, and roundtable discussions on relevant business topics.

Market Analysis

Biomarkers developments, such as biomarker signatures, are improving the treatment of neurological diseases, allowing for faster drug development and non-invasive testing. New Biomarkers are being discovered as a result of R&D. According to the Nature Journal in 2020, vitronectin is a promising Biomarkers for the diagnosis of heart failure. The market is expected to grow profitably throughout the forecast period as a result of such discoveries and technological breakthroughs. Over the next few years, It is expected that Biomarkers will be used to diagnose an increasing number of infectious diseases in the coming years. from 2022 to 2029, at a CAGR of 13.6%. The market report was curated by the Data Bridge Market Research team and includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Abbott Laboratories released Lingo, a consumer bio wearable that can track important body signals and help consumers better understand and improve their overall health, in February 2022. Biohackers may be able to use a continuous stream of data instead of periodic finger-prick tests, urine samples, and breath readings. The presence and availability of global brands, as well as the challenges they face as a result of intense or limited competition from local and domestic brands, as well as the impact of domestic brands. Only five years ago, genomic sequencing was available only in research settings. Genomic sequencing is rapidly entering clinical practise, and its integration into healthcare systems is aided by substantial government investment. National genomic-medicine initiatives are causing transformative change in real-world settings while also addressing implementation barriers and gathering evidence for broader adoption, driving market growth. As part of a $200 million public-private partnership between charities and pharmaceutical companies, the United Kingdom has announced the world's largest genome project. The country has already created the world's largest genome database through the 100,000 Genomes Project, which is led by Innovate UK as part of UK Research and Innovation. Biobanks have also paved the way for the advancement of personalised medicine, particularly the development of customised medications.

The France Biobanks market country research report is a competitive and customer intelligence study of the France market. In addition, the report provides a thorough examination of demand forecasts, market trends, and micro and macro indicators in the France market. The research also focuses on the factors that are driving and restraining the Biobanks market. This is a detailed business intelligence report that is based on both qualitative and quantitative market parameters. This report also gives readers market insights as well as a detailed analysis of market segments down to the micro level. Companies and dealers/distributors profiled in the report include Biobank manufacturers and suppliers in France.

Report on the Size, Share, and Trends of the France Cardiac Biomarker Market by Type (Creatine Kinase (CK-MB), Troponins (T, I), Myoglobin, Natriuretic Peptides (BNP & NT-PRO BNP), Ischemia Modified Albumin, and Others), Application (Myocardial Infraction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), Location of Testing The France cardiac biomarker market is expected to grow significantly at a CAGR of around 6.6% during the forecast period. The prevalence of CVD is increasing, as is the rate of diagnosis, propelling the Cardiac Biomarker market. In 2010, France had approximately 269,093 new male cases of CVD and 277,334 new female cases, according to the Global Burden of Disease Database. The number of male cases increased to 286,394 and female cases increased to 296,370.

The Biomarkers Market was valued at USD 47.35 billion in 2021, with a CAGR of 13.76% expected during the forecast period (2022-2027). The COVID-19 pandemic caused significant disruption in nearly every industry vertical. The healthcare industry experienced a similar unprecedented impact across multiple domains. However, the outbreak had a positive impact on the biomarkers market, as biomarkers are critical in the development of therapies for COVID-19 patients. Numerous studies have been conducted, and biomarkers have been discovered to play an important role in the diagnosis and treatment of COVID-19. The study, titled "Laboratory biomarkers of COVID-19 disease severity and outcome: Findings from a developing country," was published in the journal PLOS One in March 2021. suggested that timely identification of COVID-19 disease severity and mortality biomarkers would aid in providing targeted intervention and patient management. Furthermore, numerous organisations have released Biomarkers products to detect and diagnose COVID-19. Blink Science, a biotechnology and medical device company, for example, introduced blinkTEST, a handheld biosensor device that can detect COVID-19 and other disease biomarkers in saliva, in November 2020. Such developments resulted in market expansion during the pandemic phase.

The rising prevalence of various cancers is expected to increase demand for cancer Biomarkers in the near future. According to GLOBOCAN 2020, 1,414,259 new prostate cancer cases were discovered in 2020. Prostate-specific antigen is a common Biomarkers for prostate cancer (PSA). For decades, the PSA test, which detects abnormally high PSA levels in the blood, has been used to screen for and potentially diagnose prostate cancer. Furthermore, according to GLOBOCAN 2020, there will be 2,261,419 new breast cancer cases in 2020. Breast cancer biomarkers like oestrogen receptor (ER), progesterone receptor, and HER2 can be used to detect this type of cancer. Additional tools, however, are required to facilitate clinical decision-making processes.

About Conference

Biomarker 2023 Conference sincerely welcomes every one of the members over the globe to go to the "International Conference on Biomarkers" held on October 12-14, 2023 at Paris, France. with theme “Biomarkers Current Perspective and Future Prospects”

Biomarkers conference is a process of collecting innovative ideas through the analysis talks, comprehensive lectures, symposia, workshops, invited sessions and oral and poster sessions of uninvited contributions. We hope that you use this chance to fortify the permanent association and spark with the new peer around the world.The Biomarker Conferences will offer a wide platform to share vital and recent innovations in the arena of Biomarkers, Immunology, Biotechnology, Neurology, Pharmacology, Personalized medicine, Molecular Biology, Genetic and engineering It likewise has a great space for both logical introductions like oral, notice and business show.

Biomarkers Conference plans to shoot for 30 keynote presentations, 100+ oral presentations in breaking research of Biomarkers and Technologies. 200+ world-renowned experts, academicians, senior scientists, industry executives and project leaders from 50 leading countries will get together to address the topics, issues, best practices and trends necessary to make the right decisions to guide their business strategies, and future science and technology direction.

We are looking forward to meeting you in the Biomarker Conference on October 14-16,2023 at Paris, France.

Why to attend

With individuals from around the globe concentrated on finding out about Biomarkers conference and Clinical Research, this is your best chance to achieve the biggest collection of members from different famous speakers. Lead exhibitions, circulate data, meet with potential speakers/Delegates all around the globe which are chipping away at the exceptionally rising field of Biomarker conference, and get name acknowledgment at this occasion. Incredibly famous speakers, the latest procedures, strategies, and the updates in Biomarkers and Clinical Research fields are signs of this meeting.

Who Should Attend

· Scientists

· Oncologists

· Pharmacologists

· Immunologists

· Geneticists

· Biomarker Associations

· Societies of Biomarkers

· Pharmaceutical companies

· Biomedical Industrials

· Young Research fellows

· Research Students

· Medical Professors

· Faculty of Science

· Psychiatrists

Session&Tracks

Session 1: Biomarkers & Biobanking

A Biomarkers is a marker which can be precisely measured to indicate conventional biological function, pathogenic pathways, or drug response to therapeutic drug intervention. Biological markers are typically designed at the molecular level. Biological markers are found in a variety of bodily functions, including disease diagnosis and prediction, treatment response prediction and calculation, and safety assessment. These biomarkers are developed and approved for use in drug development and to support drug product approval. Biobanking is the process of collecting samples of liquid body substance or tissue for research purposes in order to better understand health and disease.

• Predisposition Biomarkers

• Diagnostic Biomarkers

• Prognostic Biomarkers

• Predictive Biomarkers

Session 2: Biomarkers in oncology

Tumor Biomarkers are biomarkers that are used to treat tumors. They aid in making precise diagnoses. Cancer Biomarkers can also distinguish whether tumors are primary or metastatic in nature. A cancer biomarker is frequently a molecule produced by a tumor or a specific body response to the presence of a tumour. Biomarkers for human prostate, breast, ovarian, and lung cancers, as well as heart disease, arthritis, asthma, and cystic fibrosis, are investigated. Biological markers can help determine the accuracy of a diagnosis and are frequently linked to other investigations to rule out cancer.

Tumor markers in cancer care
Role of biomarkers in cancer vaccines developments
Cell proliferation Biomarkers
Evaluation of Biomarkers in clinical trails

Session 3: Clinical and translational biomarkers

Clinical support detection phases and translated Biomarkers are inclined to identify the effect of compound on organs or tissues before the clinical effect is exhibited. It is frequently divided into three categories: Biomarkers for disease, target biomarkers, and mechanism biomarkers. A biomarker for translation is defined by whether it is frequently visible, quantifiable, and eventually trained or verified.

Biomarkers in clinical trials, designs
Biomarkers in strategies and application case studies
Applications of biomarkers in drug discovery

Session 4: Cardiac Biomarkers

Cardiovascular disease (CVD) is still the most prominent concern in the world. The detection of traditional risk factors such as age, hypertension, diabetes, and smoking improved CVD first-line prevention. Heart indicators are biomarkers that are measured to assess heart function. They're frequently studied in the context of a myocardial infarction, but other factors can cause an increase in the level of the gut's marker. Cardiac biomarkers are substances that are released into the bloodstream when the gut is injured or stretched. A heart marker is used to identify and stratify patients with pain and suspected acute coronary syndrome (ACS). Enzymes, hormones, and proteins are examples of these markers.

Circulatory biomarkers
Biomarkers for heart failures
Biomarkers for acute coronary syndrome
Biomarkers for metabolic syndrome

Session 5: Molecular Biomarkers

Molecular biomarkers are defined as biomarkers that will be discovered through basic and widely accepted proposals such as genomics and proteomics. This apart from genomics and proteomics platforms, biomarker assessment techniques such as metabolomics, lipidomic, and glycemic are commonly used as biomarker recognition techniques. Pathological biomarkers, macromolecule biomarkers, Insilco biomarkers, glycoprotein biomarkers, and bio-imaging markers are the different types of molecular biomarkers based on their structure and function. These biomarkers are frequently tested for biological fluids that are not abnormally composed, such as blood or serum.

Nucleic acid- based markers
Lipid biomarkers
Proteomic biomarkers
Genomic biomarkers
Micro RNA biomarkers

Session 6: Biomarkers in drug Discovery

Drug discovery using biomarkers is used solely for patient diagnosis and monitoring in clinical trials. Biological markers increase the success rates of drug advancement programmers, hastening the availability of advanced therapies. Biomarker enhancement could be a multi-step and repetitive process that begins with the discovery of biomarkers in infectious diseases. An analytical authentication phase of biomarker development, pharmacogenomics, functional proteomics, biological
analytical validation method, and pharmacokinetic models will be created during this session.

Biomarkers in Drug formulation
Biomarkers in drug design
Evaluation of dose response
Biomarkers of toxicity and pharmacology

Session 7: Breast Cancer Biomarkers

Biomarkers are crucial in the detection and management of breast cancer patients. As a result, BRCA1/2 mutation testing is used to assess risk in families with a high risk of breast and ovarian cancer. Following a breast cancer diagnosis, multi-analyte profiles such as uPA/PAI-1 or Oncotype DX may be used to determine prognosis and identify lymph node-negative patients who may be spared from adjuvant chemotherapy. Other -gene tests, such as the PAM50 ROR, Breast Cancer Index, and Endo Predict, have been shown to predict late recurrences and may be useful in selecting patients for extended hormone therapy. Burden of disease biomarkers

· Terminology for Diagnosis and prognosis

· Pharmacological Breast Cancer therapies

· Molecular Subtyping of Breast Cancer

Session 8: Blood Biomarker

Blood biomarkers are involved in auto immune dysfunction of the central nervous system. Biomarkers are not meeting a significant need in assessing prediction, response to treatment, or potential complications in treatment. There are several constraints in the process of discovering and validating an honest biomarker, such as the pathophysiological complexity of MS and thus the technical difficulties of establishing a global standard of methods for selecting, processing, and maintaining biological trials.

Biomarkers as decision making in clinical practice
Biomarkers as Alzheimer’s diseases
Biomarkers for PTSD (Post Traumatic Stress Disorder)

Session 9: Biomarkers in Pharmacology

Biological markers are important tools for drug development and research. Biological markers were recognised for making the drug development process more efficient and have become an important part of pharmacology and drug research. Several biomarkers are expected to be transferred to the clinical laboratory in the future. Biological markers show drug-dose-response relationships between changes in biomarker, onset of injury, and severity of injury as the injury evolves.

Clinical trials on Biomarker’s pharmacology
Prediction in pharmacology
Drug development in Pharmacology

Session 10: Genomics and proteomics

Biomarkers related to genomics measure changes in the amount or nature of nucleic acids. DNA-based biomarkers include copy number variation, mutations, and epigenetic changes. Quantification of mRNA, microRNA, and long non-coding RNA expression are examples of biological markers that support RNA expression. The serum proteome is made up of several small peptides that are produced as a result of various cellular activities. Proteomics is widely used in a variety of medical fields, including drug development and biomarker discovery. Proteomics has a broad impact on identifying biomarkers and revolutionising the drug development process by synchronising with other advanced genomics and bioinformatics techniques.

Technologies of proteomics and genomics
Structural and functional genomics

Session 11: Biomarker in neuro- oncology

Neurology is concerned with the diagnosis and treatment of central and peripheral systema nervosum disease, and it is one of the standard constraints in which personalised medicine has become an important part of clinical trials. Various issues in neurology should be investigated, including individualised medicine and diagnostic, prognostic, and predictive biomarkers. The importance of biomarkers and personalised medicine in neuro-oncology is growing. Several areas of neurology should discuss the current state of data.

Cerebrospinal fluid biomarkers
Biomarkers for heart failures
Biomarkers for early identification of neurological disorders

Session 12: Advancements in Biomarkers

The use of biomarkers and diagnostic evaluations is expanding, resulting in the introduction of simpler sensitivity tests. These tests are effective clinical care tools for a variety of therapeutic areas, including oncology, immunology, cardiology, and endocrinology. Recent biosensor advancements for the discovery of biomarkers in cancer therapy.

Biomarkers for Parkinson’s diseases
Gene array in addition to proteomic technologies
Urine- based biomarkers as bladder tumour antigen, nuclear matrix protein-22

Session 13: Biomarker in health and disorder

Biomarkers in health and disorders are concerned about promising findings from a pediatric autism spectrum disorder survey. The goal of the study was to evaluate the cortical and cerebrovascular development in infants aged 6 to 12 months who were at risk for ASD with children who had ASD and would experience it for up to 24 months using cerebral resonance imaging (MRI). While this study needs to be replicated in a larger group of 15 of 106 high-risk subjects who eventually developed ASD, it does highlight the significant and unmet medical need for biomarkers for neural and psychiatric disorders. Co-morbidity with other psychiatric disorders is also uncommon, leading to a dizzying array of possible diagnoses. Clinical biomarkers can assist in overcoming these limitations.

Indication for presence or absence of underlying disease states
LDL cholesterol
Blood pressure
Heart rate variability
Vital capacity

Session 14: Biomarkers for Noncancerous diseases

Biomarkers are important in the prediction and identification of a variety of cardiovascular and neurological diseases. With advances in biomarkers and various diagnostic processes and imaging technologies, diseases that are lethal with age can now be treated and diagnosed easily. Cardiac and neuro-biomarkers have revolutionised disease diagnosis and prediction. These biomarkers are also used to diagnose a variety of non-cancerous diseases. Alzheimer's disease, disorder, Huntington's chorea, condition, and diabetes are a few examples.

Risk assessment
Prognosis and treatment prediction
Monitoring treatment response

Session 15: Imaging Biomarkers

In contrast to molecular biomarkers, bio-imaging markers allow for earlier disease recognition, which optimizes translational research in drug discovery and researchers under cancer images in the market. X-ray, computerized tomography (CT), positron emission tomography (PET), single emission computerized tomography (SPECT), and resonance imaging are a few examples of image-based biomarkers (MRI).

Imaging in Neuroscience
Imaging in biomarkers in musculoskeletal system
Imaging internal tissues and organs
Imaging in clinical translation

Session 16: Digital Biomarkers

Digital biomarkers are frequently mentioned as a digital device diagnosis that will provide clinical data as significant digital data. It can forecast the physiological and behavioural findings of a patient's condition, determining what is a healthy normal stage of disease and future health outcomes. It is commonly referred to as a self-diagnostic device because it is wearable, portable, transplantable, and digestible depending on the diagnosis and condition.

E- textiles in medicines
Diagnosis of medical devices
Mobile health technologies

Session 17: Biomarkers Testing

Biological or genetic tests are a class of tests that look for molecular signs of disease so that doctors can treat them effectively. Biological markers, which serve as the foundation for accurate oncology, are critical in the organization of esophageal, breast, and lung cancers. Testing practices are rigorously scrutinized, with implications for pathologists, oncologists, and patients. Biomarker testing advances are mostly concentrated in the fields of cancer, which are divided into chromosomes, gene tests, and biochemical tests. Micro-RNA biomarker and a number of other clinical biomarkers discovered in the most recent study have paved the way for wider biomarker testing.

Fusion protein testing
Chromosome test
Biochemical test
Gene test

Session 18: Diagnostics and therapeutic Biomarkers

Biomarkers are commonly used to detect the occurrence of a disease or condition and to identify entities with a disease subtype. Diagnostic biomarkers are in agreement with the occurrence of specialized cancer examination programme (cellular and molecular pathology). Therapeutic biomarkers have a large impact on a wide range of therapeutic medications for disorder, rarity, communicable disease, and genetic disease.

Biomarkers for personalized immunotherapies
Biomarkers for cancer therapy such as Endometrial cancer, Ovarian cancer, lung cancer etc.
Emerging biomarkers for diseases like Autoimmune diseases, renal damage, cardiovascular damages etc.

Session 19: Importance of Biobanking

Biobanks are collections of human biological tissue specimens and health-related data. Biobank research aims to provide new insights into the genetic component of disease, eventually leading to a more personalized approach to healthcare. And the importance of biobanking is outlined below. The primary function of biobanks are

To collect Samples
Store biological samples
Associated clinical data

International conference on
Biomarkers and Biobanking

Quick Links

Theme: Biomarkers Current Perspective and Future Prospects

Conference Information

Welcome message

Market Analysis

About Conference

Session&Tracks